Needham Maintains Buy on G1 Therapeutics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on G1 Therapeutics (NASDAQ:GTHX), but lowers the price target from $18 to $14.
August 04, 2023 | 11:50 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst maintains a Buy rating on G1 Therapeutics but lowers the price target from $18 to $14.
The news is directly related to G1 Therapeutics. While the maintained Buy rating is positive, the lowered price target might indicate a potential downside, which could have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100